Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06842186 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of WVE-007 in Adults Living With Overweight or Obesity
A Phase 1 study of Obesity and Overweight, sponsored by Wave Life Sciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 136
- Enrollment target
- 6
- Study locations
NCT06842186: Recruiting Phase 1 study of Obesity and Overweight, sponsored by Wave Life Sciences.
NCT06842186 is a Phase 1 study of Obesity and Overweight that is actively recruiting participants, run by Wave Life Sciences. The registered enrollment target is 136 participants, below the 460-participant average among 27 other Obesity and Overweight trials with a reported enrollment target (70% lower). The trial reports 6 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06842186, a Phase 1 study of Obesity and Overweight, is actively recruiting participants, sponsored by Wave Life Sciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 136 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of WVE-007 when administered subcutaneously (SC) as single ascending doses in adults who are affected by overweight or obesity.
Conditions Studied
Interventions
- DRUG WVE-007
Study Locations (6)
Other
- ARENSIA Research Clinic - Chisinau
- Arensia Clinics S.R.L. - Bucharest
- Spitalul Clinic Judetean De Urgenta Cluj - Cluj-Napoca
- Parexel International Early Phase Clinical Unit - Harrow
- Simbec-Orion Clinical Pharmacology - Merthyr Tydfil
Maryland
- Parexel International-EPCU Baltimore - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2025-01-31 |
| Est. Completion | 2026-10 |
| Phase | Phase 1 |
What NCT06842186 shows while recruiting
NCT06842186 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, below the 460-participant average among 27 other Obesity and Overweight trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Obesity and Overweight appearing as the primary indexed condition, and to 1 intervention - of which WVE-007 is the first listed.
NCT06842186 lists 6 locations in 2 states (Other, Maryland).
Frequently Asked Questions
What is clinical trial NCT06842186 about?
NCT06842186 is a clinical study titled "A Phase 1 Study of WVE-007 in Adults Living With Overweight or Obesity". The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of WVE-007 when administered subcutaneously (SC) as single ascending doses in adults who are affected by overweight or obesity.
What is the current status of trial NCT06842186?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 136 participants. The study started on 2025-01-31. Estimated completion is 2026-10.
What conditions does trial NCT06842186 study?
This clinical trial studies the following conditions: Obesity and Overweight.
What interventions are being tested in trial NCT06842186?
The interventions under investigation include: WVE-007 (DRUG).
Who is sponsoring clinical trial NCT06842186?
This trial is sponsored by Wave Life Sciences, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06842186 being conducted?
This trial has 6 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity and Overweight
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06842186's enrollment target sits among peer trials
136 8th of 27 higher than 20 of 27 other Obesity and Overweight trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity and Overweight trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of MET233 in Individuals With Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 1
-
Metabolic Health, Bones and Nuts During Weight Loss in Adults
RECRUITING · NA
-
FAMily-centered WEight Loss for Black Adults (FAM WEL B-ing)
RECRUITING · NA
-
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
RECRUITING · Phase 3
-
New Mechanisms of Obesity
RECRUITING · NA
-
Weight Management Intervention in College: A Pilot
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI